+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in oral anticoagulation for atrial fibrillation



Recent advances in oral anticoagulation for atrial fibrillation



Therapeutic Advances in Cardiovascular Disease 4(6): 395-407



Atrial fibrillation is the most common sustained rhythm disturbance. Thromboembolic events related to atrial fibrillation result in significant morbidity, mortality and increases in the cost of healthcare. Anticoagulants are pivotal agents for the prevention and treatment of thromboembolic disorders. The latest American College of Cardiology/American Heart Association guidelines recommend antithrombotic therapy to prevent thromboembolism for all patients with atrial fibrillation, except those with lone atrial fibrillation or contraindications. Vitamin K antagonists were first synthesized in 1948 and for the past six decades they have been the only agents used for long-term oral anticoagulant therapy. Although these drugs are effective, they have numerous limitations, which have led to the development of newer anticoagulant therapies. The emerging oral anticoagulant agents are target selective. They have predictable pharmacokinetic and pharmacodynamic parameters and do not require routine monitoring. They are not associated with significant food and drug interactions, and can be administered in simple fixed daily or twice daily doses. This article reviews the current literature on various targets for anticoagulant therapy and newer oral anticoagulants for atrial fibrillation.

(PDF emailed within 0-6 h: $19.90)

Accession: 055398293

Download citation: RISBibTeXText

PMID: 20965952

DOI: 10.1177/1753944710386844


Related references

Left atrial appendage occlusion addresses the tremendous unmet needs of stroke prevention in atrial fibrillation that persist despite recent advances in anticoagulation therapy. Circulation 130(17): 1516-1523, 2014

Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. New England Journal of Medicine 333(22): 1504-1504, 1995

Whether and when oral anticoagulation therapy should be discontinued after successful ablation of atrial fibrillation. Long-term oral anticoagulation is required using either new or old anticoagulants. Giornale Italiano di Cardiologia 14(4): 278-82; Discussion 282, 2013

Oral anticoagulation for elderly patients with non-valvular atrial fibrillation: recent insights from randomised trials and the 'real world'. Heart 103(13): 977-978, 2017

Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002-2013). Journal of Epidemiology, 2017

Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. Biomed Research International 2015(): 134756-134756, 2016

Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thrombosis and Haemostasis 115(5): 1056-1063, 2016

GW26-e2303 Suboptimal oral anticoagulation use among Chinese nonvalvular Atrial Fibrillation Patients: the Nanchang Atrial Fibrillation project. Journal of the American College of Cardiology 66(16): C271-C272, 2015

What is the optimal anticoagulation intensity to prevent stroke in patients with atrial fibrillation =75 versus 75 years old? The anticoagulation and risk factors in atrial fibrillation study. Journal of the American College of Cardiology 39(5 Supplement A): 133A, March 6, 2002

Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Journal of the American Heart Association 5(7): -, 2016

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127(2): 224-232, 2013

The impact of anticoagulation intensity on severity of stroke in atrial fibrillation The anticoagulation and risk factors in atrial fibrillation study. Circulation. 106(19 Supplement): Ii-577-Ii-578, Ember 5, 2002

Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal 167(4): 601-609.E1, 2014

Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. Stroke 47(7): 1803-1810, 2016

Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation 128(7): 721-728, 2013